HRT Financial’s Inozyme Pharma INZY Stock Holding History

HRT Financial’s Portfolio INZY Stock Details INZY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-45,114	Closed	-$258K	–	2839
2023 Q1	$258K	Buy	+45,114	New	+$119K	﹤0.01%	1803

Other funds holding INZY

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

PBPIA

Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

HRT Financial's INZY Position: Q2 2023 in Review

HRT Financial sold out of Inozyme Pharma (INZY) in Q2 2023, closing a stake of 45,114 shares — an estimated $258K sold.

HRT Financial first reported a position in INZY in Q1 2023 and held it in 1 quarter. The position peaked at $258K in Q1 2023. 74 funds tracked by Wall St. Rank hold INZY as of Q2 2023.

HRT Financial reported no remaining Inozyme Pharma position as of Q2 2023 after selling out during the quarter.
HRT Financial sold 45,114 Inozyme Pharma shares in Q2 2023, an estimated $258K.
HRT Financial first reported a position in Inozyme Pharma in Q1 2023 and held it in 1 quarter.
HRT Financial's Inozyme Pharma position peaked at $258K in Q1 2023.
74 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2023.

Based on HRT Financial's 13F filing for Q2 2023, filed 11 Aug 2023.